News

Article

COVID-19 Hospital Burden Associated With Increased Inpatient Adverse Events Among Patients With, Without COVID-19

Key Takeaways

  • Increased hospital COVID-19 burden correlated with higher adverse event rates, affecting both COVID-19 and non-COVID-19 patients.
  • Hospital-acquired infections and medication-related adverse events rose with higher COVID-19 caseloads, indicating strain on hospital safety systems.
SHOW MORE

High COVID-19 hospital caseload strain led to increases in inpatient adverse events among patients both with and without SARS-CoV-2 infection.

The COVID-19 pandemic caused a surge in patients admitted to hospitals with serious effects of the virus. Accompanying strain in hospital resources has been observed as patients without COVID-19 who required hospitalization or intensive care unit treatment continues to be admitted. Although some studies have attempted to document this association, many of them did not adjust for the high severity of illness associated with COVID-19 hospitalization or incorporate hospital-specific COVID-19 results.1

Ventilator monitor and african american female patient in hospital bed with oxygen ventilator

Inpatient adverse events can be increased in frequency if hospital services are strained due to an influx of hospitalizations due to infection. | Image Credit: © wavebreak3 | stock.adobe.com

Previous research has determined an association between pandemic-related caseload strain in hospitals and adverse outcomes for patients. A trial analyzing hospital admissions and COVID-19 mortality during the SARS-CoV-2 Delta variant wave found a detrimental relationship between COVID-19 hospital caseload and survival, with 1-in-5 COVID-19 deaths being attributable to hospital caseload.2

Increased COVID-19 caseload at hospitals clearly led to widespread strain on patients with COVID-19. However, overall hospital burden during the pandemic and its effects on inpatient adverse effects (AEs) has yet to be fully analyzed. In the current trial, the investigators assessed the association between AEs among Medicare patient hospitalizations across the US and the inpatient COVID-19 burden that the hospital was contending with at the time.1,2

Patient data was garnered from the inpatient medical records of Medicare patients using the Quality and Safety Review System (QSRS). In total, data from 40,737 hospitalizations to 1210 unique hospitals were included in the analyses; 4114 hospitalizations (10.1%) were among patients with a principle or secondary diagnosis of COVID-19, while 36,623 (89.9%) were among patients without a COVID-19 diagnosis.1

During weeks with the lowest COVID-19 burden, there were 59.1 (95% CI, 54.5-64.0) AEs per 1000 admissions. For weeks with intermediate COVID-19 burden, there were 77.0 (95% CI, 73.3-80.9) AEs per 1000 admissions. Lastly, for weeks with the highest COVID-19 burden, there were 97.4 (95% CI, 91.6-103.7) AEs per 1000 admissions. Among patients without COVID-19, there were 55.7 (95% CI, 51.1-60.8) AEs per 1000 admissions during weeks with the lowest, 74.0 (95% CI, 70.2-78.1) AEs per 1000 admissions during weeks with intermediate, and 79.3 (95% CI, 73.7-85.3) AEs per 1000 admissions during weeks with the highest COVID-19 burden, with a similar pattern seen among patients with the virus, according to the investigators.1

Across the entire sample population, an increasing rate of AEs was found as hospital COVID-19 burden increased. Interestingly, for both hospital-inquired infections and medication-related AEs, incidence was more frequent as COVID-19 burden increased.1

To the investigator’s knowledge, this was the largest and most comprehensive assessment of the association of patient safety events with COVID-19 burden at the hospital level and builds off previously published studies. The Leapfrog Group had reported that hospital-acquired infections reached a 5-year high during the pandemic, concordant with data on hospital-acquired infections reported by the CDC.1,3

The current research extends these insights through linking hospital-specific AEs with weekly hospital-specific COVID-19 burden as opposed to using national COVID-19 rates. Focusing on national rates does not allow for adjustments in the variations of COVID-19 rates in different areas of the country. Ultimately, these results suggest that improvements in hospital safety regarding inpatient AEs are fragile and were not resilient to the increased stress of the pandemic.1,3

“These results illustrate the need for greater resilience, including systems of care that promote patient safety and planning for surge capacity in hospitals to prevent declines in patient safety and effectiveness of care during increases in demand, such as from pandemics, natural disasters, or other causes,” the study authors concluded.1

REFERENCES
1. Metersky ML, Rodrick D, Ho S, et al. Hospital COVID-19 burden and adverse event rates. JAMA Netw Open. 2024;7(11):e2442936. doi:10.1001/jamanetworkopen.2024.42936
2. Halpern L. Pandemic-related hospital caseload strain attributes to portion of COVID-19 deaths. Pharmacy Times. Published September 30, 2024. Accessed November 11, 2024. https://www.pharmacytimes.com/view/pandemic-related-hospital-caseload-strain-attributes-to-portion-of-covid-19-deaths
3. New Leapfrog hospital safety grade reveals significant increase in healthcare-associated infections and worsening patient experience during COVID-19 pandemic. The Leapfrog Group. May 3, 2023. Accessed September 25, 2024. https://www.leapfroggroup.org/news-events/new-leapfrog-hospital-safety-grade-reveals-significant-increase-healthcare-associated
Related Videos
Senior Doctor is examining An Asian patient.
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC